![Established Agents
• Six agents have been proven in phase III randomized trials to
benefit MS . They all affect the immune system.
• Four [the (IFNßs) and glatiramer acetate (GA)] are considered
first-line agents, while two (natalizumab and mitoxantrone)
are considered second-line agents as they have more
significant risk of side effects.
• All the (DMDs) with the exception of mitoxantrone are very
expensive; annual costs run well overUS $20,000.
• They require parenteral administration:
(SQ) or (IM) or (IV) infusion.](https://image.slidesharecdn.com/diseasemodifyingagentsformultiplesclerosis-150112220846-conversion-gate01/85/MS-Disease-modifying-agents-for-multiple-sclerosis-3-320.jpg)
![beta interferon 1b
• two brands available – Betaferon and Extavia.
• the first MS disease-modifying agent.
• IFNß1b has three molecular differences from human IFNß: it is
not glycosylated [since it is made in bacteria ( Escherichia
coli)], is missing the N terminal methionine, and has a serine
for cysteine substitution at position 17 .
• dose : 250 µg SC every other day.](https://image.slidesharecdn.com/diseasemodifyingagentsformultiplesclerosis-150112220846-conversion-gate01/85/MS-Disease-modifying-agents-for-multiple-sclerosis-6-320.jpg)
MS Disease modifying agents for multiple sclerosis
- 1. disease modifying agents for multiple sclerosis Presented by : DR : Hossam El Sayed
- 2. • Disease modifying drugs are not a cure for MS, but they can reduce the frequency of relapses. • Scientists don't yet know whether any of these drugs will slow down the rate of disability in the long term. Unfortunately they're not effective for primary progressive MS. • Clinical trials have shown that disease modifying drugs (DMDs) reduce the number of MS relapses by around a third over two years. • Current opinion favors early use for best long-term results. Since, in MS, there is accumulating permanent damage, even when patients appear stable.
- 3. Established Agents • Six agents have been proven in phase III randomized trials to benefit MS . They all affect the immune system. • Four [the (IFNßs) and glatiramer acetate (GA)] are considered first-line agents, while two (natalizumab and mitoxantrone) are considered second-line agents as they have more significant risk of side effects. • All the (DMDs) with the exception of mitoxantrone are very expensive; annual costs run well overUS $20,000. • They require parenteral administration: (SQ) or (IM) or (IV) infusion.
- 4. IFNß • IFNß is a type I anti-inflammatory/regulatory IFN. It occurs naturally in the body, but the IFNß used for treatment is produced by recombinant technology and is administered at high levels. • IFNß was initially used in MS because of its antiviral action but is now believed to be of benefit in MS due to its immunomodulatory properties. It acts systemically to decrease T cell activation, enhance suppressor cell activity, and inhibit proinflammatory cytokines. It also stabilizes the blood-brain barrier and shuts down MRI enhancement.
- 5. Major IFNß side effects • flu-like reactions in the first 12 wks after initiation of therapy. • IFNβ can produce abnormalities in - white blood cell - red blood cell and platelet counts - liver enzymes. - Thyroid function abnormalities may also occur. • Some patients report worsening of headache and episodic depression with IFNß. • Finally, the IFNßs given by SC injection are ass. with variable degrees of allergic reactions.
- 6. beta interferon 1b • two brands available – Betaferon and Extavia. • the first MS disease-modifying agent. • IFNß1b has three molecular differences from human IFNß: it is not glycosylated [since it is made in bacteria ( Escherichia coli)], is missing the N terminal methionine, and has a serine for cysteine substitution at position 17 . • dose : 250 µg SC every other day.
- 7. • There have been four placebo-controlled phase III trials with IFNß1b: - IFNß1b the original pivotal trial in relapsing MS. - two trials in SP MS (from Europe and North America). - one trial in CIS/first-attack high-risk MS. • These studies found that : - IFNß1b significantly reduced relapse rate (both annualized relapse rate and relapse frequency per patient). - increased the proportion of relapse-free patients. - decreased moderate to severe relapses. - decreased brain MRI lesion burden in relapsing MS.
- 8. IM IFNß1a (Avonex® ) • Its amino acid sequence is identical to that of human IFNß. It is glycosylated, although not necessarily in the same pattern as natural IFNβ. • dose : 30 µg IM once a week. • IM IFNß1a has been studied in two phase III trials: - In the pivotal relapsing MS trial, patients treated with IM IFNß1a showed significantly less disability than placebo as measured by sustained expanded disability status scale (EDSS) worsening, relapses, and contrast MRI lesion number and volume.
- 9. - In the CIS trial, IM IFNß1a significantly reduced occurrence of relapses (defining clinically definite MS) as well as new MRI lesion activity. • IM IFNß1a was also studied at double dose (60 µg IM weekly) in a phase III SP MS trial. Although there was a significant effect compared to placebo on worsening , there was no effect on EDSS. Ultimately, the trial was not accepted as having documented a benefit in SP MS.
- 10. SC IFNβ1a (Rebif® ) • Dose : 22 µg or 44 µg by SC injection three times a week. • pivotal relapsing trial : - evaluated 22 and 44 µg of SC IFNβ1a vs placebo. - At 2 years, both doses showed significant ability to decrease relapses, sustained disability, and MRI lesion activity. - The only difference between the two doses was that the 44 µg dose had a superior effect on decreasing T2 MRI lesion burden.
- 11. • CIS patients trial : - The dose used was very low (22 µg SC weekly vs placebo). Nevertheless, there was a significant benefit in decreasing both relapses and MRI lesion activity. • The phase III SP MS trial : - evaluated 22 and 44 µg vs placebo and basically showed results identical to that seen in the North American IFNβ1b SP MS trial i.e., no effect on EDSS progression, but a beneficial effect on relapses and MRI activity.
- 12. Glatiramer Acetate (GA) (Copaxone® ) A • made up of the acetate salts of synthetic polypeptides consisting of four amino acids . • Dose : 20 mg SC daily . • it is believed to work by : - generating GA-responsive regulatory cells that may migrate into the CNS to downregulate immune responses and subsequent damage. - It also promotes a shift from Th1 to Th2 cells. - Unlike IFNβ, GA does not appear to affect the blood-brain barrier.
- 13. • There have been three trials in relapsing MS : - The earliest one GA vs placebo treatment reduced relapses over 2 years. - The second also showed a significant benefit in reducing relapses. However, these studies did not evaluate neuroimaging. - A third trial focused on MRI Over 9 months, MRI lesion activity was significantly suppressed with GA treatment.
- 14. The major side effects of GA • injection site reactions. • 10-15% of patients experience one or more episodes of a systemic reaction/immediate postinjection reaction. This is benign and transient. It involves chest pain, palpitations, anxiety, difficulty in breathing, and flushing, and is similar to a severe panic attack. • Urticaria and lymphadenopathy can occasionally be problems.
- 15. Natalizumab (Tysabri®) • humanized monoclonal antibody directed against á 4-integrin, an adhesion molecule expressed on all leukocytes except neutrophils. • It is given every 4 weeks at a dose of 300 mg as an IV infusion over 1 h. • Natalizumab blocks cell migration into a targeted body organ (in the case of MS, the CNS) by preventing cell adhesion to endothelium. it block T cell activation and cell retention within the CNS.
- 16. • Natalizumab was evaluated in two phase III relapsing MS trials. - The monotherapy trial compared natalizumab to placebo. - the combination trial added natalizumab or placebo to patients already on IM IFNβ1a who had experienced one or more breakthrough relapses. At 2 years, patients treated with natalizumab showed significantly better suppression of relapses, disability, and MRI lesion activity.
- 17. The major side effects associated with infusion • Natalizumab is very well tolerated. • headache and fatigue. • increase in infections (respiratory and urinary tract). • gastrointestinal upset. • Hypersensitivity reactions (less than 1%) include urticaria, dizziness, flushing, chest pain, and hypotension, and occur within 2 h of infusion. • Persistent NAbs occur in 6% of patients and are ass. with increased risk for infusion hypersensitivity reactions as well as complete loss of efficacy. Persistent NAbs should lead to discontinuation of therapy.
- 18. • The major concern with natalizumab is the development of progressive multifocal leukoencephalopathy (PML). - In the original study cohort of 3,000 subjects, PML developed in three cases . - This led to a voluntary withdrawal of the drug from the marketplace for over a year before it was reintroduced in late June 2006 .
- 19. Mitoxantrone (Novantrone®) • an antineoplastic anthracenedione. It intercalates into DNA, causing cross-links and strand breaks. It is cytotoxic for both proliferating and nonproliferating cells and inhibits B cells, T cells, and monocytes/macrophages. • dose : 12 mg/m 2 by IV infusion every 3 months. The lifetime maximum dose in MS is 140 mg/m 2 . This limit reflects concerns about accumulating cardiomyopathy risk.
- 20. adverse effects • Mitoxantrone is a second-line agent because it carries risk for significant adverse effects. These include : - cardiomyopathy. - treatment-related leukemia, leukopenia, and infection. - menstrual disorders/infertility. It is generally used in patients who have failed first-line treatments. In recent trials, short-term mitoxantrone (for 3−6 months) has been used as induction therapy, to be followed by first-line therapy.
- 21. • The major mitoxantrone trial entered relapsing and SP MS cases: - randomized to one of three arms: placebo, and 5 mg/m 2 or 12 mg/m 2 of mitoxantrone for 2 years. - The 12 mg/m 2 dose showed the clearest benefit on relapse, disability, and MRI parameters.
- 22. Other agents • There are a number of other agents that are still used to treat MS, even though they have not been established for use by phase III trials. • These can be divided into immunosuppressant and immunomodulatory approaches.
- 23. Immunosuppression • Azathioprine: This is a purine antagonist which affects DNA replication. It affects T cells more than B cells and is considered to have a better safety profile than cyclophosphamide or methotrexate. • Bone marrow transplantation: The concept is to reset immunological memory directed against autoantigens. • Cyclophosphamide (Cytoxan® ) is an alkylating agent which binds to DNA, and interferes with DNA and RNA synthesis. It affects both B and T cells, modulates the cytokine production network in MS, and crosses the BBB. It has been used principally in rapidly deteriorating relapsing MS and early progressive MS.
- 24. Immune modulation • Methotrexate: Methotrexate is an antimetabolite agent that also suppresses chemokine expression (CXCR3 and CCR4) and inflammatory cytokine production. • IV immunoglobulin is accepted therapy for several peripheral nervous system immune-mediated disorders, but it has not been documented convincingly to benefit MS. • Plasma exchange, similar to IV immunoglobulin therapy, is not a proven treatment for MS.
- 25. THANK YOU